Acquisition is more defensive than offensive. Premium like that indicates there was a bidding war. Look out for the Stryker lawyers unload on anyone infringing on the huge NVDQ patent portfolio. But it also let's Stryker go head to head with Storz and Olympus in the ICG and NBI markets. Roll the IP into the Stryker Endo suite and start cashing checks!
ICG is different technology to Storz SPIES and Olympus NBI. And Stryker is already promoting ICG in the 1588 platform. They've just acquired the only other current ICG technology I'm aware of at a massive premium. Very interesting.
love the technology from Nova and can see it being a huge value add for us. Does this mean that are spending spree is done for the year with a huge acqusition like Novadaq? Are we out of the neurostimulation pool and whats next on the buying block?
Actually its the Stryker reps that will be RIFd in MASS Numbers. Stryker overspent on this acquisition and you'll see the impact by fall. If you dont think so, then you're a damn blind fool.
The idiots that run this company will probably fire all the Novadaq reps, and dump more shit on us! The Novadaq rep that I run into, really knows his shit, and seems to be well liked by docs and staff alike. Let them do their thing! We have enough to do!!!
Come on. Novadaq probably has a grand total of 50 reps in North America. They'll keep some, dump some, and bring in Stryker guys to fill the gaps. Total sales head count to remain about the same. Stryker will slash Novadaq G&A, and a big chunk of R&D. Those are where they'll find the synergies, not in net sales force reductions.
Sounds like another player is about the make a higher bid for Novadaq. JnJ? Medtronic? Intuitive? Suppose that Stryker will counter but this is a fun game to watch.